Ernst-guenter Afting - Net Worth and Insider Trading
Ernst-guenter Afting Net Worth
The estimated net worth of Ernst-guenter Afting is at least $89,623 dollars as of 2024-11-13. Ernst-guenter Afting is the Director of Sequenom Inc and owns about 37,499 shares of Sequenom Inc (SQNM) stock worth over $89,623. Details can be seen in Ernst-guenter Afting's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Ernst-guenter Afting has not made any transactions after 2008-12-09 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Ernst-guenter Afting
Ernst-guenter Afting Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Ernst-guenter Afting owns 3 companies in total, including Enanta Pharmaceuticals Inc (ENTA) , Sorrento Therapeutics Inc (SRNE) , and Sequenom Inc (SQNM) .
Click here to see the complete history of Ernst-guenter Afting’s form 4 insider trades.
Insider Ownership Summary of Ernst-guenter Afting
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ENTA | Enanta Pharmaceuticals Inc | 2013-03-20 | director |
| SRNE | Sorrento Therapeutics Inc | 2010-02-05 | director |
| SQNM | Sequenom Inc | 2013-06-11 | director |
Ernst-guenter Afting Latest Holdings Summary
Ernst-guenter Afting currently owns a total of 1 stock. Ernst-guenter Afting owns 37,499 shares of Sequenom Inc (SQNM) as of December 9, 2008, with a value of $89,623.
Latest Holdings of Ernst-guenter Afting
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| SQNM | Sequenom Inc | 2008-12-09 | 37,499 | 2.39 | 89,623 |
Holding Weightings of Ernst-guenter Afting
Ernst-guenter Afting Form 4 Trading Tracker
According to the SEC Form 4 filings, Ernst-guenter Afting has made a total of 0 transactions in Sequenom Inc (SQNM) over the past 5 years. The most-recent trade in Sequenom Inc is the sale of 6,300 shares on December 9, 2008, which brought Ernst-guenter Afting around $104,076.
Insider Trading History of Ernst-guenter Afting
- 1
Ernst-guenter Afting Trading Performance
GuruFocus tracks the stock performance after each of Ernst-guenter Afting's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Ernst-guenter Afting is 108.6%. GuruFocus also compares Ernst-guenter Afting's trading performance to market benchmark return within the same time period. The performance of stocks bought by Ernst-guenter Afting within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Ernst-guenter Afting's insider trading performs compared to the benchmark.
Performance of Ernst-guenter Afting
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 8.6 | | | | | |
| Relative Return to S&P 500(%) | 6 | | | | | |
Ernst-guenter Afting Ownership Network
Ownership Network List of Ernst-guenter Afting
Ownership Network Relation of Ernst-guenter Afting
Ernst-guenter Afting Owned Company Details
What does Enanta Pharmaceuticals Inc do?
Who are the key executives at Enanta Pharmaceuticals Inc?
Ernst-guenter Afting is the director of Enanta Pharmaceuticals Inc. Other key executives at Enanta Pharmaceuticals Inc include Chief Medical Officer Scott T. Rottinghaus , Sr. VP & New Product Dev. Tara Lynn Kieffer , and Sr. VP & Business Dev. Brendan Luu .
Enanta Pharmaceuticals Inc (ENTA) Insider Trades Summary
Over the past 18 months, Ernst-guenter Afting made no insider transaction in Enanta Pharmaceuticals Inc (ENTA). Other recent insider transactions involving Enanta Pharmaceuticals Inc (ENTA) include a net sale of 12,479 shares made by Scott T. Rottinghaus , a net sale of 9,391 shares made by Tara Lynn Kieffer , and a net sale of 15,295 shares made by Terry Vance .
In summary, during the past 3 months, insiders sold 0 shares of Enanta Pharmaceuticals Inc (ENTA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 53,756 shares of Enanta Pharmaceuticals Inc (ENTA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 53,756 shares.
Enanta Pharmaceuticals Inc (ENTA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Enanta Pharmaceuticals Inc Insider Transactions
Ernst-guenter Afting Mailing Address
Above is the net worth, insider trading, and ownership report for Ernst-guenter Afting. You might contact Ernst-guenter Afting via mailing address: C/o Sorrento Therapeutics, Inc., 6042 Cornerstone Ct., Suite B, San Diego Ca 92121.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
